The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGFbeta), including TGFbeta1, TGFbeta2 and TGFbeta3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGFbeta expression.
